Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) said Nasdaq granted a 180-day extension to regain compliance with the minimum bid price rule, extending the cure period to June 29, 2026. The company must have a closing bid of $1.00 or more for 10 consecutive business days before that date to regain compliance. If compliance is not achieved during the extension, Nasdaq will notify the company that its common stock will be delisted, and the company may appeal to a hearings panel with no assurance of success. Nasdaq's notice does not affect current listing or trading, and the company says it will monitor the bid price and evaluate options to regain compliance.
Positive
- Nasdaq granted a 180-day extension to regain compliance
- Extension deadline set for June 29, 2026
- Listing and trading continue on Nasdaq during extension
- Clear cure condition: $1.00 close for 10 business days
Negative
- Shares currently below Nasdaq minimum bid price requirement
- Risk of delisting if compliance not met by June 29, 2026
- No assurance an appeal to a hearings panel would succeed
News Market Reaction 5 Alerts
On the day this news was published, MODD gained 0.55%, reflecting a mild positive market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $150K to the company's valuation, bringing the market cap to $27M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MODD was down 7.23% ahead of this news, while close medical-device peers showed mixed moves (e.g., ECOR -3.13%, MYO -1.15%, IINN +1.35%, RBOT +1.64%), pointing to stock-specific pressures rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Equity offering priced | Negative | -30.5% | Underwritten public offering pricing with significant discount and attached warrants. |
| Dec 09 | Offering proposed | Negative | +2.1% | Announcement of proposed equity and warrant offering from existing shelf. |
| Nov 17 | IRB approval | Positive | -2.6% | IRB approval for in-house study using Pivot patch pump with CGM wearers. |
| Nov 14 | 510(k) submission | Positive | +11.2% | Submission of Pivot tubeless insulin patch pump for FDA 510(k) clearance. |
| Nov 03 | Manufacturing milestone | Positive | +12.4% | Successful validation of Pivot controller manufacturing line for high-volume production. |
Recent capital-raising announcements drew sharp downside reactions, while operational and regulatory progress updates for the Pivot pump more often coincided with positive moves.
Over the last few months, Modular Medical combined product milestones with balance sheet moves. In November 2025, it validated the Pivot controller line and submitted the Pivot 510(k), with those updates seeing double-digit percentage gains in the stock. IRB approval for an in-house Pivot study followed on November 17, 2025. In December 2025, the company announced and then priced a $4.68 million public offering, after which shares fell more than 30%. Today’s Nasdaq bid-price extension comes against this backdrop of dilution and ongoing commercialization plans.
Market Pulse Summary
This announcement highlights that Modular Medical received a 180‑day Nasdaq extension to regain compliance with the $1.00 minimum bid requirement, pushing the deadline to June 29, 2026. The company must achieve at least 10 consecutive trading days at or above that level to avoid a potential delisting process. Investors may track progress on commercializing the Pivot insulin patch pump, capital-raising activities, and any further Nasdaq communications as key factors for the listing outlook.
Key Terms
minimum bid price requirement regulatory
Nasdaq Capital Market regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / December 31, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced the Company received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5810(c)(3)(A) (the "Bid Price Rule"). The Company now has until June 29, 2026 to meet the requirement. If at any time prior to June 29, 2026, the bid price of the Company's common stock closes at
If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a Hearings Panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.
The Company will continue to monitor the closing bid price of its common stock and evaluate its available options to regain compliance with the Bid Price Rule.
Nasdaq's extension notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the ticker symbol, "MODD."
Safe Harbor/Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's ability to regain compliance with the Bid Price Rule, the Company's plans to consider implementing available options to regain compliance with the Bid Price Rule and the Company's intention to appeal any future delisting determination. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risk that the Company may not meet the minimum bid price requirement during any compliance period or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, and represent views only as of the date they are made and should not be relied upon as representing views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.
About Modular Medical, Inc.
Modular Medical, Inc. (NASDAQ:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
What deadline did Modular Medical (MODD) receive from Nasdaq to regain compliance?
What is the Nasdaq cure condition Modular Medical (MODD) must meet?
Will Modular Medical (MODD) remain listed while it seeks compliance?
What happens if Modular Medical (MODD) fails to regain compliance by June 29, 2026?
Does Modular Medical (MODD) have assurance an appeal against delisting would succeed?
How will Modular Medical (MODD) respond while under the Nasdaq extension?
